Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydralazine in ADPKD
NCT03423810Phase 1Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydralazine in autosomal dominant polycystic kidney disease (ADPKD), sponsored by University of Kansas Medical Center. Primary endpoints: polycystin-1 at 8 weeks and mucin-like protocadherin at 8 weeks. Started Apr 2018; status: completed.
02
Drugs
hydralazine
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03423810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423810.